Correction: Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings

Lisa A de Jong, Jessie Groeneveld, Jelena Stevanovic, Harrie Rila, Robert G Tieleman, Menno V Huisman, Maarten J Postma, Marinus van Hulst

Research output: Contribution to journalErratum

1 Citation (Scopus)
31 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Correction: Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases